# NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)

> **NCT05996003** · PHASE2 · RECRUITING · sponsor: **NS Pharma, Inc.** · enrollment: 20 (estimated)

## Conditions studied

- Duchenne Muscular Dystrophy
- Exon 44
- DMD

## Interventions

- **DRUG:** NS-089/NCNP-02

## Key facts

- **NCT ID:** NCT05996003
- **Lead sponsor:** NS Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-22
- **Primary completion:** 2026-09-11
- **Final completion:** 2026-09-11
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05996003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05996003, "NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05996003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*